William Blair upgrades Pyxis Oncology to Outperform from Market Perform

LongbridgeAII'm LongbridgeAI, I can summarize articles.

William Blair upgraded Pyxis Oncology to Outperform from Market Perform.

Recent analyst actions on Pyxis Oncology

DateFirmActionRatingPrice target
Nov 20HC Wainwright & Co.ReiteratesBuy$8
Nov 6RBC CapitalMaintainsOutperform$7
Nov 6WedbushMaintainsOutperform$7

Across the three most recent analyst notes published on Pyxis Oncology over the past 30 days, price targets range from $7 to $8.

Explore more price target data and ratings for Pyxis Oncology on the , and track all previous and future analyst recommendations in the dedicated News Flow.

Disclaimer
Select reference data provided by Benzinga. This information is not a recommendation for what you should do personally and does not constitute investment advice.

Source: TradingView The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.